The transcription factor NKX2.1, expressed at high levels in the medial ganglionic eminence (MGE), is a 31 master regulator of cortical interneuron progenitor development. To identify gene candidates with 32 expression profiles similar to NKX2.1, previous transcriptome analysis of human embryonic stem cell 33 (hESC)-derived MGE-like progenitors revealed SFTA3 as the strongest candidate. Quantitative real-time 34 PCR analysis of hESC-derived NKX2.1-positive progenitors and transcriptome data available from the 35 Allen Institute for Brain Science revealed comparable expression patterns for NKX2.1 and SFTA3 during 36 interneuron differentiation in vitro and demonstrated high SFTA3 expression in the human MGE. 37 Although SFTA3 has been well studied in the lung, the possible role of this surfactant protein in the MGE 38 during embryonic development remains unexamined. To determine if SFTA3 plays a role in MGE 39 specification, SFTA3-/-and NKX2.1 -/-hESC lines were generated using custom designed CRISPRs. We 40 show that NKX2.1 KOs have a significantly diminished capacity to differentiate into MGE interneuron 41 subtypes. SFTA3 KOs also demonstrated a somewhat reduced ability to differentiate down the MGE-like 42 lineage, although not as severe relative to NKX2.1 deficiency. These results suggest NKX2.1 and SFTA3 43 are co-regulated genes, and that deletion of SFTA3 does not lead to a major change in the specification of 44 MGE derivatives. 45 Introduction: 46 During early embryonic development of the mammalian telencephalon, the transcription factor 47 NKX2.1 is highly expressed in the medial ganglionic eminence (MGE), a subpallidal structure of the 48 ventral forebrain (1-3). The MGE and caudal ganglionic eminence (CGE) are transient embryonic 49 structures that are the primary source of GABAergic inhibitory progenitors, which migrate tangentially to 50 target sites in the cortex. These progenitors then differentiate into a number of diverse inhibitory 51 interneuron subtypes that modulate the activity of excitatory projection neurons in the cerebral cortex (3-52 8). Expression of the homeobox protein NKX2.1 is a requirement for specification of the MGE and its 53 derivatives. NKX2.1 deficient mice display gross malformations of the ganglionic eminences and a
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To identify gene candidates with expression profiles similar to NKX2.1 that could also help 62 specify the MGE lineage, we utilized previously published data from our laboratory comparing the RNA-63 seq-based transcriptome of FACS isolated human embryonic stem cell (hESC) -derived NKX2.1-positive 64 progenitors to NKX2.1-negative cells. This analysis showed that the profile of surfactant associated 3 65 (SFTA3) expression closely followed NKX2.1, suggesting it was a novel MGE marker that could be 66 involved in interneuron specification (12). 
132
Guide RNA sequences were cloned into addgene plasmid #62988. The dual sgRNA vector was 133 electroporated into H9 hESC cells using a Gene Pulser X (250 V, 500 uF). Cells were plated and after 24 134 hours, puromycin was supplemented into the medium at 1 ug/ml. Puromycin was added for a total of 48 135 hours to select for the transient expression of the dual sgRNA vectors. After 14 days, clones were
136 isolated, expanded and tested by PCR. Clones were screened for deletion, inversion, and zygosity by 137 PCR. Double KO clones were further expanded and sequenced across the junction to confirm genomic 138 deletion. The same procedures described above were performed to derive control lines with the exception 139 that no gRNA sequence was used during vector electroporation.
140

Culture of ESCs and MGE-like cells
141 hESC SFTA3 and NKX2.1 control and KO cell lines were maintained and passaged as previously 146
In vitro maturation of hESNPs 147
The addition of the ROCK inhibitor Y27632 (1 µM, Calbiochem) was supplemented into every medium 148 change of SFTA3 control and KO progenitors beginning at differentiation day 21 until day of fixation.
149 Immunocytochemistry
150
The fixation, permeabilization, and incubation of primary and secondary antibodies were performed as We used RNA-sequencing analysis to compare the transcriptome of NKX2.1-positive and NKX2.1-170 negative neural progenitors to identify genes whose expression was enriched in the NKX2.1-positive 171 MGE-like population. SFTA3 expression was consistently enriched in the NKX2.1-positive population, 172 and to the same extent observed for NKX2.1 (>8 fold gene enrichment) (Chen et al., 2016; Figure 1A ).
173
The expression values for SFTA3 are comparable to NKX2.1, with a correlative-coefficient R value >0.98;
174 indicating strong statistical significance in fold change enrichment between these two genes
175
( Supplementary Table 1 ).
176
We used RT-PCR analysis to examine expression levels of these two genes at specific time points 177 during the differentiation of hESC-derived interneurons. Both genes were upregulated in a similar time 178 course, consistent with shared regulatory elements ( Figure 1B) . Recently, an enhancer sequence region 179 that may confer ventral forebrain expression was identified on chromosome 14 near the NKX2.1 and 181 the transcription of both SFTA3 and NKX2.1. Additionally, immunocytochemistry revealed a large 182 percentage of neural progenitors at day 26 of differentiation co-expressed NKX2.1 and SP-H ( Figure 1C ).
183
To investigate whether SFTA3 is expressed during the development of the human fetal brain, we 184 examined transcriptome data from the BrainSpan Atlas. The Atlas indicates enrichment of SFTA3 in the 185 MGE at 8 post-conception weeks (pcw) ( Figure 1D ). Furthermore, when comparing the expression levels 186 of SFTA3 to all brain structures at 8 pcw, the MGE is the only structure to demonstrate a significant 187 elevation in expression of the gene ( Figure 1D ). These results suggest that SFTA3 is a novel biomarker 188 specific to the MGE during early ventral forebrain development. Figure 1A) . In addition, the deletion of NKX2.1 199 significantly reduced SFTA3 transcript levels, suggesting NKX2.1 is needed to maintain control levels of 200 SFTA3 gene expression (Supplementary Figure 1A) . Both SFTA3 KO cell lines had no detectable RNA 201 transcripts for SFTA3. Interestingly, NKX2.1 RNA expression is not significantly affected in SFTA3 KO 202 lines (Supplementary Figure 1B ; Figure 2B ). We also examined levels of protein expression for these two Figure 2D) . Surprisingly, the percentage of cells expressing DCX, a post- Figure. 3 A, B) . Day 45 258 neurons generated from the NKX2.1 KO line exhibited minimal GABA expression, (< 1%) relative to 259 control cells at this time point (> 38%), consistent with a role for NKX2.1 in conferring GABAergic 260 inhibitory identity. Immunocytochemistry-based quantification of SFTA3 mutants indicated ~10%
261
GABA expression in both SFTA3 knockout lines compared to ~18% expression in the control,
262
demonstrating that the deletion of SFTA3 did not eliminate neural progenitor differentiation down the 263 GABAergic lineage ( Figure 3A, B) . and CGE-associated genes at the expense of MGE marker expression ( Figure 2A) . Surprisingly, at day 
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The orthologue of the human SFTA3 gene in rodents is NANCI, which appears to encode a long 
